FDA expands early access to Revolution Medicines pancreatic cancer drug daraxonrasib after late-stage trial nearly doubled survival.
Median 13.2 months versus 6.7 on chemo
Read the full story at USA Today
From the May 1, 2026 GovBrief, every story that day in one place.